Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2022 - Market Size, Current Insights and Development Trends

Global PROteolysis Targeting Chimera (PROTAC) Market Research Report 2022 - Market Size, Current Insights and Development Trends

The report focuses on the PROteolysis Targeting Chimera (PROTAC) market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.

Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the PROteolysis Targeting Chimera (PROTAC) market.

Major Players in the PROteolysis Targeting Chimera (PROTAC) market are:

Cullgen
Kymera Therapeutics, Inc.
Genentech
C4 Therapeutics
Amgen
AstraZeneca
Bayer
Merck
Arvinas
Vividion
Pfizer

On the basis of types, the PROteolysis Targeting Chimera (PROTAC) market is primarily split into:

ARV-110
ARV-471
KYM-001
Others

On the basis of applications, the market covers:

Oncology
Others

Major Regions or countries covered in this report:

United States

Europe

China

Japan

India

Southeast Asia

Latin America

Middle East and Africa

Others

Years considered for this report:

Historical Years: 2017-2021

Base Year: 2021

Estimated Year: 2022

Forecast Period: 2022-2029